Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P23025

UPID:
XPA_HUMAN

ALTERNATIVE NAMES:
Xeroderma pigmentosum group A-complementing protein

ALTERNATIVE UPACC:
P23025; Q5T1U9; Q6LCW7; Q6LD02

BACKGROUND:
The DNA repair protein complementing XP-A cells is integral to the DNA excision repair pathway, specifically targeting and binding to UV-induced DNA damage sites. Its ability to recruit necessary repair factors and initiate the repair process underscores its vital role in preserving cell health and preventing mutations that could lead to cancer.

THERAPEUTIC SIGNIFICANCE:
The association of this protein with Xeroderma pigmentosum complementation group A, a disease characterized by extreme sensitivity to sunlight and a predisposition to skin cancers, underscores its therapeutic potential. Exploring the mechanisms of this protein could lead to breakthroughs in treatments for skin cancer and other UV-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.